Primary regulatory
FDA Warning Letters to Peptide Sellers: Enforcement Database
FDA warning letters database showing enforcement actions against online peptide sellers who market products as research-use-only while making therapeutic claims, providing dosing guidance, or implying human use. Includes warning letters to Gram Peptides and others in the peptide space.
U.S. Food and Drug AdministrationPublished 2026-07-08Accessed 2026-07-08
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-peptide-warning-letters
Source usage
Linked from 15 pages
Guide
FDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuideFDA Warning Letter Tracker: Enforcement Actions Against Peptide Sellers
GuideHow to Evaluate a Peptide Supplier
GuideHow to Read a COA (Certificate of Analysis)
GuidePayment Processing for Peptide Businesses
GuidePeptide Business Compliance Guide: Labeling, Claims, COAs, and FDA Enforcement for RUO Sellers
GuidePeptide Storage Guide: Lyophilized, Reconstituted, and Degradation
GuidePeptide Terminology Glossary
Research hubCommunity Guidelines: What's Allowed and Not Allowed in Peptide Discussions
Research hubCompounded Peptides Explained: 503A vs 503B
Research hubPeptide Community Hub: Reddit, YouTube, Telegram, and Discord Spaces
Research hubRUO Marketplace Risk Guide: How to Evaluate Marketplace Risk Without Buying
Research hubRUO vs Telehealth: How People Access Peptides
Research hubUser-Submitted Supplier Reviews: A Moderated Framework for Sharing Supplier Documentation Experiences
Research hubWhat Does 'Research Use Only' Actually Mean?
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.